NanoViricides' Pediatric Safety Data for NV-387 Could Unlock Trials for Ebola, Mpox, and Measles

NanoViricides reported positive juvenile animal safety results for its broad-spectrum antiviral NV-387, potentially enabling pediatric clinical trials for Ebola, Mpox, and measles, though the company also disclosed going concern doubt.

Chicago Metrowire Staff
••Healthcare
NanoViricides' Pediatric Safety Data for NV-387 Could Unlock Trials for Ebola, Mpox, and Measles

NanoViricides, Inc. (NYSE American: NNVC) announced positive results from a juvenile mouse study evaluating the safety, tolerability, and toxicity of its broad-spectrum antiviral drug NV-387, supporting its potential advancement into pediatric clinical trials. The 12-day repeated-dose study found that NV-387 Oral Gummies were well tolerated at all tested dose levels, with no mortality, systemic toxicity, or treatment-related adverse effects. The highest tested dose of 3,690 mg/kg/day was established as the No Observed Adverse Effect Level (NOAEL), and no maximum tolerated dose was identified.

The company believes these findings could support pediatric enrollment in future clinical trials for Ebola, Mpox, and measles, subject to further clinical development and regulatory requirements. NV-387 is currently being evaluated in Phase II clinical trials for Ebola and Mpox in the Democratic Republic of Congo, and the drug has received U.S. Food and Drug Administration orphan drug and rare pediatric disease designations for measles. The positive juvenile safety data are critical because they suggest the drug may be safe for children, a population particularly vulnerable to these infectious diseases.

However, NanoViricides also disclosed that its fiscal 2026 annual report included an auditor statement expressing substantial doubt about its ability to continue as a going concern. The company is pursuing potential nondilutive funding for clinical development while maintaining access to equity-based financing, including an at-the-market share offering facility. This financial uncertainty contrasts with the clinical progress and underscores the challenges of funding antiviral development.

The implications of the safety results are significant. If NV-387 proves safe and effective in pediatric trials, it could become a much-needed broad-spectrum antiviral for children, especially in outbreak settings where Ebola and measles can cause high mortality. The orphan drug and rare pediatric disease designations for measles may provide incentives such as market exclusivity and priority review, potentially accelerating development. Moreover, the ongoing Phase II trials in the DRC for Ebola and Mpox are a testament to the drug's potential in real-world outbreak scenarios.

NanoViricides is a clinical-stage company creating special-purpose nanomaterials for antiviral therapy. Its lead drug candidate, NV-387, is being developed as a treatment for RSV, COVID, Long COVID, influenza, and other respiratory viral infections, as well as Mpox/smallpox and measles. The company's other advanced candidate is NV-HHV-1 for shingles. For more information, visit www.nanoviricides.com. The full press release is available at https://ibn.fm/5QClt, and the latest news and updates relating to NNVC are available in the company's newsroom at https://ibn.fm/NNVC.

MissionIR, a specialized communications platform, distributed the announcement. MissionIR is part of the Dynamic Brand Portfolio at IBN, which provides access to wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions. For more information, visit MissionIR. Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer.

Blockchain Registration

QR Code for Blockchain Registration